CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Inhaled ILOPROSTWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Inhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory Failure

Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is thought to be the main cause of respiratory failure in COVID-19 patients. Research is still ongoing to further elucidate the different ARDS subtypes that may exist in COVID-19. It is crucial to find new targets for treatment and support of COVID-19 patients with respiratory failure.

NCT04445246 COVID-19 ARDS, Human Hypoxemic Respiratory Failure Drug: Inhaled ILOPROST
MeSH:Respiratory Insufficiency Respiratory Distress Syndrome, Adult

Primary Outcomes

Description: change in oxygen saturation and PaO2/FiO2 ratio by 20% on day 6 compared to baseline values prior to Iloprost initiation.

Measure: change in oxygenation parameters

Time: 5 days

Secondary Outcomes

Description: likelihood to require intubation in the cohort treated with Iloprost

Measure: Rates of endotracheal intubation

Time: 28 days

Description: in days in the cohort treated with Iloprost

Measure: Invasive ventilation duration

Time: 28 days

Description: in days in the cohort treated with Iloprost

Measure: ICU length of stay

Time: 28 days

Description: in days in the cohort treated with Iloprost

Measure: Hospital Length of stay

Time: 28 days

Description: likelihood to require proning in the cohort treated with Iloprost

Measure: Rates of proning therapy

Time: 28 days

Description: likelihood to require ECMO cannulation in the cohort treated with Iloprost

Measure: Rates of ECMO cannulation

Time: 28 days

Description: likelihood to die of any cause within 28 days of initial hospital presentation

Measure: Mortality

Time: 28 days


No related HPO nodes (Using clinical trials)